Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively - Patient enrollment in Phase.
REDWOOD CITY, Calif., Dec. 18, 2023 Jasper Therapeutics, Inc. , a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit in mast cell-driven.
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.